Pfizer Inc (PFE)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $164.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
Pfizer Inc (PFE) Financials: Revenue, Profit and Cash Flow
Pfizer reported revenue of $62.58B for the fiscal year ended Dec 31, 2025, down 1.6% from the year before. That year, net income was $7.81B with a net margin of 12.5%, operating cash flow was $11.70B and free cash flow was $9.07B. The quarter ended Sep 30, 2026 had revenue of $16.58B and net income of $3.25B.
Revenue and Margins
The operating margin was 22.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $52.82B, a compound annual rate of 1.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $62.58B | -1.6% | 74.3% | 22.8% | 12.5% |
| Dec 2024 | $63.63B | +6.8% | 71.9% | 19.5% | 12.7% |
| Dec 2023 | $59.55B | -41.1% | 58.1% | 2.1% | 3.6% |
| Dec 2022 | $101.17B | +24.5% | 66.1% | 35.4% | 31.0% |
| Dec 2021 | $81.29B | +95.2% | 62.1% | 23.9% | 27.1% |
| Dec 2020 | $41.65B | +1.8% | 79.6% | 19.8% | 22.1% |
| Dec 2019 | $40.91B | +0.2% | 80.3% | 16.4% | 39.3% |
| Dec 2018 | $40.83B | -22.3% | 78.0% | 13.9% | 27.4% |
| Dec 2017 | $52.55B | -0.5% | 78.6% | 26.1% | 40.6% |
| Dec 2016 | $52.82B | N/A | 76.7% | 23.0% | 13.7% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 3.1% from the year before. In the quarter ended Sep 2026, net income fell 8.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B | $41.65B | $40.91B | $40.83B | $52.55B | $52.82B |
| Cost of revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B | $11.23B | $12.32B |
| Gross profit | $46.51B | $45.78B | $34.60B | $66.83B | $50.47B | $33.17B | $32.85B | $31.84B | $41.32B | $40.50B |
| Research and development | $12.05B | $10.93B | $10.87B | $12.38B | $13.83B | $9.39B | $8.38B | $7.76B | $7.68B | $7.89B |
| Operating income | $14.24B | $12.41B | $1.28B | $35.79B | $19.43B | $8.25B | $6.71B | $5.67B | $13.72B | $12.14B |
| Net income | $7.81B | $8.06B | $2.16B | $31.41B | $22.02B | $9.20B | $16.06B | $11.19B | $21.36B | $7.25B |
| EBITDA | N/A | $15.04B | $7.35B | $39.79B | $29.50B | $11.72B | $8.97B | $9.74B | $18.57B | $14.11B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.58B | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.71B | $17.76B | $17.70B | $13.28B | $14.88B | $14.57B |
| Gross profit | $12.55B | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B | $10.87B | $11.85B | $12.44B | $9.98B | $11.50B | $7.01B |
| Operating income | $3.67B | $3.06B | $4.03B | $2.87B | $3.85B | $3.78B | $3.74B | $2.35B | $4.96B | $1.00B | $4.10B | -$4.29B |
| Net income | $3.25B | -$237.00M | $2.70B | -$1.64B | $3.55B | $2.93B | $2.97B | $418.00M | $4.47B | $48.00M | $3.12B | -$3.36B |
Balance Sheet
As of Dec 2025, total debt of $64.80B exceeded cash and equivalents by $63.65B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.47B | $154.23B | $167.59B | $159.42B | $171.80B | $171.62B |
| Current assets | $42.90B | $50.36B | $43.33B | $51.26B | $59.69B | $35.07B | $32.80B | $49.93B | $41.14B | $38.95B |
| Cash and equivalents | $1.14B | $1.04B | $2.85B | $416.00M | $1.94B | $1.79B | $1.12B | $1.14B | $1.34B | $2.60B |
| Total liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B | $90.76B | $104.15B | $95.66B | $100.14B | $111.78B |
| Short-term debt | $3.15B | $6.95B | $10.35B | $2.94B | $2.24B | $2.70B | $16.20B | $8.83B | $9.95B | $10.69B |
| Long-term debt | $61.64B | $57.41B | $61.54B | $32.88B | $36.20B | $37.13B | $35.95B | $32.91B | $33.54B | $31.40B |
| Shareholder equity | $86.48B | $88.20B | $89.01B | $95.66B | $77.20B | $63.24B | $63.14B | $63.41B | $71.31B | $59.54B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $204.54B | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B | $221.09B | $226.50B |
| Total liabilities | $115.24B | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B | $126.92B | $128.22B | $128.54B | $137.21B |
| Cash and equivalents | $1.82B | $976.00M | $1.70B | $1.14B | $1.34B | $1.64B | $1.43B | $1.04B | $1.09B | $1.05B | $719.00M | $2.85B |
| Shareholder equity | $89.00B | $85.19B | $90.10B | $86.48B | $92.80B | $88.69B | $90.34B | $88.20B | $92.29B | $87.70B | $92.28B | $89.01B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 77.5% of operating cash flow. Dividends came to 107.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B | $12.59B | $15.83B | $16.80B | $16.19B |
| Capital expenditures | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B | $2.23B | $2.05B | $1.98B | $1.96B | $1.82B |
| Free cash flow | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B | $12.18B | $10.54B | $13.84B | $14.85B | $14.37B |
| Dividends paid | $9.77B | $9.51B | $9.25B | $8.98B | $8.73B | $8.44B | $8.04B | $7.98B | $7.66B | $7.32B |
| Share repurchases | N/A | N/A | N/A | $2.00B | $0 | $0 | $8.87B | $12.20B | $5.00B | $5.00B |
| Investing cash flow | -$1.35B | $2.65B | -$32.28B | -$15.78B | -$22.55B | -$4.27B | -$3.94B | $4.53B | -$4.74B | -$7.79B |
| Financing cash flow | -$10.30B | -$17.14B | $26.07B | -$14.83B | -$9.82B | -$9.65B | -$8.48B | -$20.44B | -$13.35B | -$9.23B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.38B | $835.00M | $2.62B | $5.35B | $4.60B | -$582.00M | $2.33B | $6.72B | $6.71B | -$1.78B | $1.09B | $5.24B |
| Capital expenditures | $573.00M | $533.00M | $436.00M | $845.00M | $602.00M | $618.00M | $564.00M | $917.00M | $651.00M | $637.00M | $704.00M | $1.04B |
| Free cash flow | $4.80B | $302.00M | $2.18B | $4.50B | $4.00B | -$1.20B | $1.77B | $5.80B | $6.06B | -$2.42B | $386.00M | $4.20B |
Frequently Asked Questions About PFE
What is Pfizer's annual revenue?
Pfizer reported revenue of $62.58B for the fiscal year ended Dec 31, 2025.
How fast is Pfizer's revenue growing?
Revenue was down 1.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -14.8%.
Is Pfizer profitable?
Yes. Pfizer reported net income of $7.81B for the fiscal year ended Dec 31, 2025, with a net margin of 12.5%.
How much free cash flow does PFE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $11.70B minus capital expenditures of $2.63B produced free cash flow of $9.07B.
How much debt does Pfizer have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $61.64B, short-term debt of $3.15B and cash and equivalents of $1.14B.
PFE pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts